UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000057842
Receipt number R000066014
Scientific Title Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis
Date of disclosure of the study information 2025/05/12
Last modified on 2026/11/11 11:31:30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis

Acronym

Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis

Scientific Title

Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis

Scientific Title:Acronym

Tranexamic Acid in Patients with Traumatic Hemorrhagic Shock: A Systematic Review and Meta-analysis

Region

Japan


Condition

Condition

Traumatic Hemorrhagic Shock Patients

Classification by specialty

Emergency medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To assess the Efficacy and Safety of Tranexamic Acid in Traumatic Hemorrhagic Shock Patients

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Functional Outcome

Key secondary outcomes

Adverse Event
Total Blood Product Usage
ICU Length of Stay
Hospital Length of Stay
Short-term Mortality
Long-term Mortality


Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Randomized controlled trial including more than 50% of patients with traumatic hemorrhagic shock

Key exclusion criteria

Conference abstract
Language other than English

Target sample size



Research contact person

Name of lead principal investigator

1st name Nobuto
Middle name
Last name Nakanishi

Organization

Kobe University Graduate School of Medicine

Division name

Division of Disaster and Emergency Medicine, Department of Surgery Related

Zip code

650-0017

Address

7-5-2 Kusunoki, Chuo-ward, Kobe, 650-0017, Japan

TEL

0783826521

Email

nobuto_nakanishi@yahoo.co.jp


Public contact

Name of contact person

1st name Nobuto
Middle name
Last name Nakanishi

Organization

Kobe University Graduate School of Medicine

Division name

Division of Disaster and Emergency Medicine, Department of Surgery Related

Zip code

650-0017

Address

7-5-2 Kusunoki, Chuo-ward, Kobe, 650-0017, Japan

TEL

0783826521

Homepage URL


Email

nobuto_nakanishi@yahoo.co.jp


Sponsor or person

Institute

Kobe university

Institute

Department

Personal name



Funding Source

Organization

The Japanese Association for the Surgery of Trauma

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Kobe University Graduate School of Medicine

Address

7-5-2 Kusunoki, Chuo-ward, Kobe, 650-0017, Japan

Tel

078-382-6521

Email

nobuto_nakanishi@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW

兵庫県


Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2025 Year 05 Month 12 Day


Related information

URL releasing protocol

https://www.dropbox.com/scl/fi/icvxruarrz324b0606hil/3_protcol_link-to-umine_20250514.pdf?rlkey=quxq

Publication of results

Unpublished


Result

URL related to results and publications

None

Number of participants that the trial has enrolled

22516

Results

Favorable functional outcomes did not differ between the TXA and control groups (RR 1.01, 95% CI 0.99-1.03; 2 trials, n=21,258). TXA reduced short-term mortality (RR 0.89, 95% CI 0.82-0.96). Hospital stay was shorter with TXA (mean difference -1.13 days), but this exploratory finding was based on only 2 studies (n=188). No significant differences were found in adverse events, blood product use, or long-term mortality.

Results date posted

2026 Year 10 Month 26 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Adult patients with traumatic hemorrhagic shock. Traumatic hemorrhagic shock was defined as traumatic hemorrhage accompanied by hemodynamic instability according to the prespecified eligibility criteria of each included study. As the definitions of hemodynamic instability differed across trials, no uniform post hoc threshold was applied. Studies were included when the study population was explicitly described as having hemorrhagic shock or when more than or equal to 50% of patients were judged by to have hemorrhagic shock.

Participant flow

An extensive search of three databases yielded a total of 2,166 records. Of these, 301 duplicate records were removed, leaving 1865 records for title and abstract screening. Based on the eligibility criteria, 1,833 records were excluded following title and abstract screening, and 32 reports were sought for retrieval. One report could not be retrieved. Therefore, 31 full-text reports were assessed for eligibility. Ultimately, five RCTs (22516 patients) were included in this systematic review and meta-analysis.

Adverse events

All adverse events were included in the analysis; five studies encompassing 22,516 patients assessed adverse events . TXA did not increase the occurrence of adverse events (RR, 0.82; 95% CI, 0.55 to 1.22; very low CoE). Owing to the overall high risk of bias in one study, certainty in risk of bias was downgraded one level. Imprecision was considered serious because the CI spanned two zones. Considering the study size and the pattern of effect estimates across studies, publication bias was considered serious, causing the overall CoE to be downgraded to very low certainty.

Outcome measures

The primary outcome was (1) favorable functional outcome, based on each study's criteria. The secondary outcomes encompassed (2) adverse events; (3) total blood product usage; (4) length of ICU (intensive care unit) stay; (5) hospital length of stay; (6) short-term mortality (30-day or in-hospital mortality); and (7) long-term mortality.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2025 Year 05 Month 12 Day

Date of IRB

2025 Year 05 Month 12 Day

Anticipated trial start date

2025 Year 05 Month 12 Day

Last follow-up date

2025 Year 05 Month 12 Day

Date of closure to data entry

2025 Year 11 Month 11 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information

This study is a systematic review and meta-analysis; therefore, no patient enrollment is required.
Subgroup analyses will be performed based on the following factors: (1) timing of tranexamic acid administration, (2) dosage of tranexamic acid, and (3) site of trauma.


Management information

Registered date

2025 Year 05 Month 12 Day

Last modified on

2026 Year 11 Month 11 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000066014